- Home
- HQL vs PACB Comparison
HQL vs PACB Comparison
Compare HQL & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HQL | PACB |
|---|---|---|
| Founded | 1992 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 507.9M | 419.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | HQL | PACB |
|---|---|---|
| Price | $17.88 | $1.60 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 108.7K | ★ 5.5M |
| Earning Date | 01-01-0001 | 05-07-2026 |
| Dividend Yield | ★ 11.56% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | N/A | $11.32 |
| Revenue Next Year | N/A | $12.13 |
| P/E Ratio | $22.59 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $11.72 | $0.85 |
| 52 Week High | $17.96 | $2.73 |
Technical Indicators
Market Signals| Indicator | HQL | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 69.24 | 59.76 |
| Support Level | $16.40 | $1.52 |
| Resistance Level | N/A | $1.64 |
| Average True Range (ATR) | 0.35 | 0.10 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 96.26 | 86.90 |
Price Performance
Historical ComparisonAbout HQL abrdn Life Sciences Investors Shares of Beneficial Interest
abrdn Life Sciences Investors operates as a non-diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation by investing mainly in securities of life sciences companies. It invests in securities of public and private companies that are believed by the Fund's Investment Adviser to have the potential for above-average growth.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.